TNFSF11 and immune system disorder: TRANCE/RANKL has been shown to suppress proinflammatory cytokine production in mouse model (Maruyama et al., 2006); however, in humans, the RANKL gene mutations do not result in an increased risk of immune disorders and its inhibitor (denosumab) has no significant effect on inflammatory processes (Ferrari‐Lacraz & Ferrari, 2011).